Related Experiment Videos
Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation
Helen M Evans1, Patrick J McKiernan, Deirdre A Kelly
1The Liver Unit, Birmingham Children's Hospital, Birmingham B4 6NH, UK. helenevans@doctors.org.uk
Transplantation
|June 9, 2005
Summary
Mycophenolate mofetil (MMF) improved renal function in 92% of children after liver transplants, allowing reduced use of calcineurin inhibitors. This immunosuppressant is safe and effective for pediatric post-transplant renal dysfunction.
Area of Science:
- Pediatric Nephrology
- Transplantation Immunology
- Pharmacology
Background:
- Calcineurin inhibitors like cyclosporine A (CsA) and tacrolimus (Tac) are standard immunosuppressants post-liver transplant but cause nephrotoxicity.
- Mycophenolate mofetil (MMF) is an alternative immunosuppressant with a favorable renal profile.
- Long-term efficacy and safety of MMF in pediatric patients with post-orthotopic liver transplant (OLT) renal dysfunction remain under-evaluated.
Purpose of the Study:
- To evaluate the long-term effectiveness and safety of MMF in children experiencing renal dysfunction after OLT.
- To assess the impact of MMF on calculated glomerular filtration rate (cGFR) and liver function.
- To identify factors influencing MMF response in this pediatric population.
Main Methods:
- Retrospective analysis of pediatric patients with renal dysfunction (cGFR < 65 mL/min/1.73 m²) post-OLT treated with MMF.
- Monitoring of cGFR and liver function before and after MMF initiation.
- Statistical analysis using the Wilcoxon signed rank test.
Main Results:
- 92% of patients showed significant cGFR improvement within 2 months of MMF treatment, with sustained gains.
- Younger children (age < 3 years at OLT) and those starting MMF earlier post-OLT exhibited greater cGFR increases.
- MMF was generally well-tolerated, with uncommon side effects and rare instances of graft dysfunction.
Conclusions:
- MMF is a safe and effective immunosuppressant for pediatric patients with renal dysfunction post-OLT.
- Switching to MMF can improve renal function and allow reduction or discontinuation of nephrotoxic agents (CsA, Tac).
- Consideration of steroid co-administration during MMF transition may mitigate rejection risk.